Jennifer Herron
Director/Board Member chez Gwynedd-Mercy Academy
Profil
Jennifer L.
Herron is a Trustee at Gwynedd-Mercy Academy.
She previously worked as an Independent Director at ChemoCentryx, Inc. and Genocea Biosciences, Inc. She was also the Vice President-US Immunology at Bristol Myers Squibb Co. from 2006 to 2016.
In addition, she served as the Chief Commercial Officer & Executive Vice President at ImmunoGen, Inc. in 2019, and as the President & Executive VP-Global Commercial at MorphoSys AG and Bio-Rad AbD Serotec, Inc. She started her career as an Associate at Boehringer Mannheim Pharmaceuticals Corp.
Ms. Herron's education includes an undergraduate degree from Lehigh University and an MBA from Georgetown University.
Currently, she is a Trustee at Gwynedd-Mercy Academy and the Chief Commercial Officer & Senior Vice President at ADC Therapeutics SA.
Postes actifs de Jennifer Herron
| Sociétés | Poste | Début |
|---|---|---|
| Gwynedd-Mercy Academy | Director/Board Member | - |
Anciens postes connus de Jennifer Herron
| Sociétés | Poste | Fin |
|---|---|---|
| ADC THERAPEUTICS SA | Corporate Officer/Principal | 17/11/2022 |
| CHEMOCENTRYX, INC. | Director/Board Member | 20/10/2022 |
| IMMUNOGEN, INC. | Corporate Officer/Principal | 01/03/2019 |
| ARIAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/04/2017 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2016 |
Formation de Jennifer Herron
| Lehigh University | Undergraduate Degree |
| Georgetown University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| IMMUNOGEN, INC. | Health Technology |
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| MORPHOSYS AG | Health Technology |
| ADC THERAPEUTICS SA | Health Technology |
| Entreprise privées | 5 |
|---|---|
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
Bio-Rad AbD Serotec, Inc.
 Bio-Rad AbD Serotec, Inc. Medical SpecialtiesHealth Technology Bio-Rad AbD Serotec, Inc. manufactured and supplied monoclonal and polyclonal antibodies to the research community. The company was headquartered in Raleigh, NC. | Health Technology |
| Boehringer Mannheim Pharmaceuticals Corp. | |
| Gwynedd-Mercy Academy |
